Getting insurance after genetic screening on familial hypercholesterolaemia; the need to educate both insurers and the public to increase adherence to national guidelines in the Netherlands

Journal Article (2002)
Author(s)

Perla J. Marang-van de Mheen (Universiteit van Amsterdam)

Merel C. Van Maarle (Universiteit van Amsterdam)

Marlies E.A. Stouthard (Universiteit van Amsterdam)

Affiliation
External organisation
DOI related publication
https://doi.org/10.1136/jech.56.2.145
More Info
expand_more
Publication Year
2002
Language
English
Affiliation
External organisation
Issue number
2
Volume number
56
Pages (from-to)
145-147

Abstract

Heterozygous familial hypercholesterolaemia (FH) is a common autosomal dominant inherited metabolic disease with a prevalence of 1 in 500 in most Western countries. People with FH experience an increased risk for coronary artery disease (CAD) and excess mortality especially at a young age. Until recently the diagnosis of FH was based on clinical signs and symptoms alone. These included increased cholesterol concentrations, in particular of LDL-cholesterol, in combination with the presence of tendon xanthoma, corneal arcus, xanthelasmata and a history of early CAD. Frequently FH was diagnosed after a first cardiac event.

No files available

Metadata only record. There are no files for this record.